Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection
Rosalinda Madonna(University of Chieti-Pescara), Giuseppe Mercuro(University of Cagliari), Alessia Pepe(Fondazione Toscana Gabriele Monasterio), Christian Cadeddu Dessalvi(University of Cagliari), Pasquale Pagliaro(Ospedale San Luigi Gonzaga), Ines Monte(University of Catania), Concetta Zito(University of Messina), Carlo G. Tocchetti(Federico II University Hospital), Martino Deidda(University of Cagliari), Paolo Spallarossa(Ospedale Policlinico San Martino), Giuseppina Novo(AOL (United States)), Donato Mele(University of Ferrara)
Cited by 45
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal - Cardiovascular Imaging|2022|486
Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)
|European Journal of Heart Failure|2020|364